Edition:
India

Karo Pharma AB (KARO.ST)

KARO.ST on Stockholm Stock Exchange

38.00SEK
25 Mar 2019
Change (% chg)

-- (--)
Prev Close
38.00kr
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
826,148
52-wk High
45.35kr
52-wk Low
25.25kr

About

Karo Pharma AB, formerly known as Karo Bio AB, is a Sweden-based biopharmaceutical company engaged in the research and development of drugs based on the nuclear receptors. The Company’s pipeline comprises three projects: Estrogen Receptor Beta (ERbeta) cancer, a platform, which focuses on the development of ERbeta in cancer... (more)

Overall

Beta: 0.71
Market Cap(Mil.): kr3,270.22
Shares Outstanding(Mil.): 82.17
Dividend: 0.28
Yield (%): 0.70

Financials

Private equity firm EQT increases offer for Sweden's Karo Pharma

STOCKHOLM, Jan 2 Private equity firm EQT on Wednesday bumped up its offer for Swedish specialty pharma group Karo Pharma to 6.15 billion Swedish crowns ($694 million), citing in part stock market performance since its original offer two months ago.

02 Jan 2019

Karo Pharma says Chairman Anders Lonner has died

STOCKHOLM, Dec 3 Speciality pharma firm Karo Pharma's Chairman Anders Lonner has died, the company said in a statement on Sunday evening.

03 Dec 2018

Deals of the day-Mergers and acquisitions

Oct 29 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday:

30 Oct 2018

Private equity firm EQT launches $654 million cash bid for Sweden's Karo Pharma

STOCKHOLM Private equity firm EQT on Monday made a recommended 5.97 billion Swedish crown ($654 million) cash bid to buy Swedish specialty pharma group Karo Pharma.

29 Oct 2018

Private equity firm EQT launches $654 mln cash bid for Sweden's Karo Pharma

STOCKHOLM, Oct 29 Private equity firm EQT on Monday made a recommended 5.97 billion Swedish crown ($654 million) cash bid to buy Swedish specialty pharma group Karo Pharma.

29 Oct 2018

Earnings vs. Estimates